HERTHENA-Lung01: A Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic <i>EGFR</i> -mutated NSCLC-Reference-Cited by-同舟云学术

HERTHENA-Lung01: A Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic EGFR -mutated NSCLC

Published:2023-05-22 Issue:19 Volume:19 Page:1319-1329
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncol.

Author:

Yu Helena A¹,Yang James Chih-Hsin²^ORCID,Hayashi Hidetoshi³^ORCID,Goto Yasushi⁴^ORCID,Felip Enriqueta⁵^ORCID,Reck Martin⁶^ORCID,Vigliotti Michele⁷,Dong Qian⁷,Cantero Frédérique⁷,Fan Pang-Dian⁷^ORCID,Kanai Masayuki⁷,Sternberg David W⁷,Jänne Pasi A⁸^ORCID

Affiliation:

1. Department of Medicine, Medical Oncology,Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

2. Department of Oncology,National Taiwan University Hospital, Taipei City, 100, Taiwan

3. Department of Medical Oncology,Kindai University, Osaka, 589-8511, Japan

4. Department of Thoracic Oncology,National Cancer Center Hospital, Tokyo, 104-0045, Japan

5. Medical Oncology Department,Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, 08035, Barcelona, Spain

6. Department of Thoracic Oncology, LungenClinic, Airway Research Center North,German Center for Lung Research, 22927, Grosshansdorf,Germany

7. Oncology Clinical Development,Daiichi Sankyo, Basking Ridge, NJ 07920, USA

8. Medical Oncology,Dana-Farber Cancer Institute, Boston, MA 02215, USA

Funder

Daiichi-Sankyo

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.2217/fon-2022-1250

Reference42 articles.

1. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review;Stewart EL;Transl. Lung Cancer Res.,2015

2. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

3. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer

4. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

5. Third generation EGFR TKIs: current data and future directions

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody–drug conjugates for breast cancer: a bibliometric study and clinical trial analysis;Discover Oncology;2024-08-02

2. Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review;European Journal of Pharmacology;2024-08

3. Drug development and evidence for lung cancer targeted therapy in Eastern Asia;The Lancet Regional Health - Western Pacific;2024-08

4. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28

5. Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation;Annals of Oncology;2024-07